Guggenheim raised the firm’s price target on Inventiva (IVA) to $13 from $9 and keeps a Buy rating on the shares. The firm has updated its estimates based on “increased enthusiasm” for the Metabolic-Associated Steatohepatitis market and at-launch target patient population, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- 3 Best Stocks to Buy Now, 8/28/2025, According to Top Analysts
- Inventiva initiated with an Overweight at Piper Sandler
- Inventiva’s Strategic Positioning and Promising Developments Drive Buy Rating
- Inventiva’s Strong Financial Position and Promising Phase 3 Trial Drive Buy Rating
- Inventiva Announces Preliminary First-Half 2025 Financial Results